By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...
Pfizer is positioning its experimental medicine as a competitor to Eli Lilly's (LLY) Zepbound and Novo Nordisk's (NVO) Wegovy, which are both weekly GLP-1 injections, after it re-entered the ...
The pharmaceutical giant (PFE) said two doses from a Phase 2b study of the once-a-month injection demonstrated weight reduction of 10% and 12.3% after 28 weeks in adults with obesity or overweight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results